1. Home
  2. IRD vs CRIS Comparison

IRD vs CRIS Comparison

Compare IRD & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • CRIS
  • Stock Information
  • Founded
  • IRD 2018
  • CRIS 2000
  • Country
  • IRD United States
  • CRIS United States
  • Employees
  • IRD N/A
  • CRIS N/A
  • Industry
  • IRD
  • CRIS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IRD
  • CRIS Health Care
  • Exchange
  • IRD NYSE
  • CRIS Nasdaq
  • Market Cap
  • IRD 36.1M
  • CRIS 32.8M
  • IPO Year
  • IRD N/A
  • CRIS 2000
  • Fundamental
  • Price
  • IRD $1.15
  • CRIS $3.22
  • Analyst Decision
  • IRD Strong Buy
  • CRIS Strong Buy
  • Analyst Count
  • IRD 1
  • CRIS 3
  • Target Price
  • IRD $8.00
  • CRIS $23.00
  • AVG Volume (30 Days)
  • IRD 153.1K
  • CRIS 39.9K
  • Earning Date
  • IRD 02-19-2025
  • CRIS 02-14-2025
  • Dividend Yield
  • IRD N/A
  • CRIS N/A
  • EPS Growth
  • IRD N/A
  • CRIS N/A
  • EPS
  • IRD N/A
  • CRIS N/A
  • Revenue
  • IRD $8,381,000.00
  • CRIS $10,259,000.00
  • Revenue This Year
  • IRD N/A
  • CRIS N/A
  • Revenue Next Year
  • IRD $29.37
  • CRIS N/A
  • P/E Ratio
  • IRD N/A
  • CRIS N/A
  • Revenue Growth
  • IRD N/A
  • CRIS 0.44
  • 52 Week Low
  • IRD $0.81
  • CRIS $2.86
  • 52 Week High
  • IRD $2.77
  • CRIS $17.49
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • CRIS 47.34
  • Support Level
  • IRD N/A
  • CRIS $3.05
  • Resistance Level
  • IRD N/A
  • CRIS $3.55
  • Average True Range (ATR)
  • IRD 0.00
  • CRIS 0.24
  • MACD
  • IRD 0.00
  • CRIS 0.03
  • Stochastic Oscillator
  • IRD 0.00
  • CRIS 47.53

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About CRIS Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Share on Social Networks: